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ABSTRACT 
Recent fate-mapping studies in mice have provided substantial evidence that mature adult 
hepatocytes are a major source of new hepatocytes following liver injury. In other systems, 
integrin αvβ8 has a major role in activating transforming growth factor beta (TGFβ), a 
potent inhibitor of hepatocyte proliferation. We hypothesized that depletion of hepatocyte 
integrin αvβ8 would increase hepatocyte proliferation and accelerate liver regeneration 
following injury. Using Itgb8flox/flox;Alb-Cre mice to deplete hepatocyte αvβ8, following 
partial hepatectomy, hepatocyte proliferation and liver-to-body weight ratio were 
significantly increased in Itgb8flox/flox;Alb-Cre mice compared to control. Antibody-mediated 
blockade of hepatocyte αvβ8 in vitro, with assessment of TGFβ signaling pathways by qPCR 
array, supported the hypothesis that integrin αvβ8 inhibition alters hepatocyte TGFβ 
signaling towards a pro-regenerative phenotype. A diethylnitrosamine-induced model of 
hepatocellular carcinoma, employed to examine the possibility that this pro-proliferative 
phenotype might be oncogenic, revealed no difference in either tumor number or size 
between Itgb8flox/flox;Alb-Cre and control mice. Immunohistochemistry for integrin αvβ8 in 
healthy and injured human liver demonstrated that human hepatocytes express integrin 
αvβ8. Depletion of hepatocyte integrin αvβ8 results in increased hepatocyte proliferation 
and accelerated liver regeneration following partial hepatectomy in mice. These data 
demonstrate that targeting integrin αvβ8 may represent a promising therapeutic strategy to 
drive liver regeneration in patients with a broad range of liver diseases. 
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INTRODUCTION 
 
Although the liver has a unique ability to regenerate, in many cases of liver disease this 
regenerative capacity is overwhelmed. A successful pro-regenerative therapy for the liver 
could have widespread application, reducing the need for transplantation in both acute and 
chronic liver failure, and potentially allowing more patients with primary or metastatic liver 
cancer to be treated successfully. Recent fate-mapping studies in mice have provided strong 
evidence that, in most murine models of liver injury and regeneration, restoration of liver 
mass occurs predominantly through self-duplication of hepatocytes.1,2 Hence, identifying 
targets that promote proliferation and expansion of the pre-existent hepatocyte population 
represents an attractive therapeutic approach to drive liver regeneration. 
 
Transforming growth factor beta (TGFβ) has pleiotropic roles in liver disease. In addition to 
its role as a major pro-inflammatory cytokine,3 TGFβ is also a potent repressor of 
hepatocyte proliferation.4-7 Therefore, in principle, TGFβ inhibition appears an attractive 
therapeutic strategy to promote hepatocyte proliferation and liver regeneration. An ideal 
therapy would target TGFβ with precision, allowing hepatocytes to escape the mito-
inhibitory effects of TGFβ, while not abrogating the positive effects of TGFβ on extracellular 
matrix production and vascular remodeling during the regenerative process.8,9 Furthermore, 
pan-TGFβ blockade may result in a number of unwanted, off-target effects, such as 
induction of autoimmunity and hepatocarcinogenesis.10-12 Therefore, a more nuanced, 
selective approach targeting the TGFβ pathway to promote liver regeneration is required. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 5
TGFβ is predominantly stored within the extracellular matrix in a latent state, and much of 
the regulation of TGFβ function results from precise, temporally and spatially restricted, 
extracellular activation of this latent complex.13 The αv integrins, transmembrane 
heterodimeric proteins comprising an αv subunit and one of the five β subunits, bind to an 
arginine-glycine-aspartate (RGD) motif present on the tip of an exposed loop within the 
latency-associated peptide that maintains TGFβ in an inactive state.14 All five αv integrins 
have been shown to interact with the RGD motif present in the latency-associated 
peptide.15-19 This integrin-RGD interaction, in the presence of mechanical force supplied by 
the integrin-expressing cell, enables the release of the active TGFβ homodimer.20 
 
Inhibition of myofibroblast αv integrins in mice reduces fibrosis in multiple organs via a 
reduction in TGFβ activation.21 Furthermore, combined global knockout of integrins αvβ6 
and αvβ8 phenocopies the developmental effects of loss of TGFβ-1 and -3.22 In the liver, 
expression of integrin αvβ6 appears restricted to activated cholangiocytes, transitional 
hepatocytes, and oval cells during biliary and portal fibrosis.23,24 Conversely, αvβ8 
expression by hepatic cell types has not been well-characterized. Integrin αvβ8 has been 
shown to play an important role in TGFβ activation in other systems, including dendritic 
cells,25-27 regulatory T cells,28 neuroepithelium,29 and in fibroinflammatory airway disease.30 
Further, integrin αvβ8 inhibits proliferation of lung epithelium via TGFβ activation.31 
Therefore, given the important role of αvβ8 in mediating TGFβ activation in other organ 
systems and pathologies, we investigated the role of hepatocyte integrin αvβ8 in the 
context of liver regeneration. We hypothesized that depletion of integrin αvβ8 from 
hepatocytes would reduce local activation of TGFβ and result in increased hepatocyte 
proliferation and accelerated liver regeneration following liver injury. 
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MATERIALS AND METHODS 
 
Mice 
Albumin-Cre (Alb-Cre) mice32 were obtained from the Jackson Laboratory (Bar Harbor, ME), 
crossed with Itgb8flox/flox mice33 obtained from L. Reichardt, and the resulting Itgb8flox/flox;Alb-
Cre mice were maintained on a C57BL/6 background. Pdgfrb-Cre mice (also on a C57BL/6 
background) were obtained from R. Adams.34 Mice used for all experiments were 8- to 16-
week–old and were housed under specific pathogen–free conditions in the Animal Barrier 
Facility of the University of California, San Francisco, or the University of Edinburgh, UK. 
Genotyping of all mice was performed by PCR. Sample size was determined statistically prior 
to experimentation. Age- and sex-matched littermate controls were used for all 
experiments. Investigators were blinded to mouse genotype and experimental order was 
decided randomly. All experimental animal procedures were approved by the Institutional 
Animal Care and Use Committee of the University of California, San Francisco, or performed 
in accordance with the UK Home Office regulations. 
 
Two-thirds partial hepatectomy 
Two-thirds of the liver was surgically removed under isoflurane anesthesia as previously 
described.35 All surgeries were performed in the first half of the day. To label proliferating 
hepatocytes, 5-bromo-2-deoxyuridine (BrdU (Roche), Sigma-Aldrich, Gillingham, UK) was 
injected two hours prior to liver harvest (100 mg/kg intraperitoneally). Mice and livers were 
weighed at harvest to calculate liver-to-body weight ratio. 
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Hepatocarcinogenesis model 
Male mice were injected with diethylnitrosamine (DEN, Sigma-Aldrich) at 12  to 14 days (25 
mg/kg intraperitoneally). Mice were sacrificed at 40 weeks, and macroscopic tumors 
counted and measured. 
 
Liver biochemistry 
Whole blood was collected immediately post mortem, allowed to clot, and serum obtained 
by centrifugation (9391g for 5 minutes twice). Samples were frozen at -20 °C pending 
analysis. Serum albumin, total bilirubin, alanine transaminase (ALT), and alkaline 
phosphatase (ALP) measurements were determined using commercial kits (Alpha 
Laboratories, Eastleigh, UK [albumin, bilirubin, ALT]; Randox Laboratories, Crumlin, County 
Antrim, UK [ALP]) adapted for use on a Cobas Fara centrifugal analyzer (Roche Diagnostics, 
Welwyn Garden City, UK). 
 
Immunohistochemistry 
Liver samples were fixed overnight at room temperature in either methacarn (60% 
methanol, 30% chloroform, 10% acetic acid), for BrdU immunohistochemistry (IHC), or 10% 
neutral buffered formalin. Samples were then paraffin-embedded prior to sectioning. 
BrdU IHC: endogenous peroxidases were quenched with 0.3% H2O2 in methanol, followed 
by consecutive 10-minute incubation steps with 0.1% trypsin (Sigma-Aldrich, T7168), warm 
1.8M HCl, and 0.1M sodium tetraborate decahydrate (Sigma-Aldrich, S9640). Blocking and 
subsequent incubation steps utilized the Mouse on Mouse Elite Peroxidase Kit (Vector 
Laboratories, Peterborough, UK, PK2200). Primary antibody was mouse anti-BrdU (Dako, 
Agilent Technologies, Cheadle, UK, M0744 – 1:40). Detection was performed using the Elite 
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Vectastain ABC kit (Vector, PK7100) and DAB (Dako, K3468), before counterstaining, 
dehydration, and mounting. For each liver sample, approximately 3,000 hepatocytes were 
counted to calculate the percentage of proliferating hepatocytes. 
 
GR1 (neutrophil)/F4/80 (Kupffer cell)/PDGFRβ (hepatic stellate cell (HSC)) IHC: antigen 
retrieval was performed with Tris-EDTA (PDGFRβ only), endogenous peroxidases were 
quenched with 3% H2O2, Avidin/Biotin block was applied (Vector, SP-2001) before blocking 
with 20% goat serum (GR1/PDGFRβ) or rabbit serum (F4/80). Primary antibodies were 
applied for two hours at room temperature (PDGFRβ, Abcam, Cambridge, UK, ab32570 – 
1:500) or overnight at 4 °C (GR1, R&D, Abingdon, UK, Mab 1037 – 1:750; F4/80, Abcam, 
ab6640 – 1:200). Secondary antibody (PDGFRβ – biotinylated goat anti-rabbit (Vector, BA-
1000 – 1:1000); GR1 – biotinylated goat anti-rat (Vector, BA-9401 – 1:1000); F4/80 – 
biotinylated rabbit anti-rat (Vector, BA-4001 – 1:200)) was applied for 30 minutes at room 
temperature. Detection was performed using the Elite Vectastain ABC kit and DAB, before 
counterstaining, dehydration, and mounting. For each sample, 10 sequential fields were 
acquired at x20 magnification and percentage positive staining calculated using FIJI.36 
 
β8 integrin subunit/Cleaved Caspase-3 IHC: antigen retrieval was performed with Tris-EDTA 
(β8 integrin subunit) or sodium citrate (cleaved caspase-3), endogenous peroxidases were 
quenched with 3% H2O2, before blocking with 20% horse serum. Primary antibody (β8 
integrin subunit, Abcam, ab80673 – 1:500; Cleaved Caspase-3, Cell Signaling Technology, 
Leiden, The Netherlands, 9664 – 1:1000) was applied overnight at 4 °C. Detection was 
performed using the ImmPRESS Polymerized Reporter Enzyme Staining System (Vector, 
MP7401) and DAB, before counterstaining, dehydration, and mounting. 
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Hematoxylin and eosin staining: sections were baked at 55 oC overnight, before de-waxing 
and rehydration. Slides were then placed in Harris Hematoxylin (Thermo Fisher Scientific, 
Paisley, UK) for five minutes. After washing, slides were placed in 1% acid alcohol for five 
seconds, followed by Scott’s tap water for two minutes. Slides were then transferred to 
Eosin Y solution (Thermo Fisher Scientific) for two minutes, followed by washing, 
dehydration, and mounting. For quantification of mitotic figures, a minimum of 1,000 
hepatocytes were counted per sample. 
 
No image processing was performed prior to quantitative analysis. Images presented in 
figures were contrast-enhanced by adjusting intensity minima and maxima. Images to be 
compared were processed identically and in a manner that preserved the visibility of dim 
and bright structures in the original image. 
 
Primary mouse hepatocyte isolation 
Primary mouse hepatocytes were isolated by retrograde perfusion of the liver with Liver 
Perfusion Medium (Thermo Fisher Scientific), followed by Liver Digest Medium (Thermo 
Fisher Scientific) at 37 °C. When hepatocytes were visually dispersed within the liver 
capsule, the liver was removed to a sterile dish and minced with scissors to release the 
crude cell isolate. The cells were then suspended in DMEM/F-12 (Thermo Fisher Scientific) 
and pelleted twice. Hepatocytes were purified from the washed pellets by resuspension in 
culture medium and centrifugation through 50% equilibrated Percoll (GE Healthcare Life 
Sciences, Little Chalfont, UK). 
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Standard primary hepatocyte culture 
Primary hepatocytes were isolated as described above, resuspended in low-serum medium 
(DMEM (Thermo Fisher Scientific), 2.5% Fetal Bovine Serum (Thermo Fisher Scientific), 2% L-
Glutamine (Thermo Fisher Scientific), 1% Penicillin Streptomycin (Thermo Fisher Scientific)), 
and plated onto collagen-coated wells (Collagen Type I, Millipore, Watford, UK) in a 6-well 
plate at a density of 500,000 cells per well. Either β8 integrin subunit blocking antibody26 or 
non-binding control antibody were added at 20µg/mL and samples were incubated for 24 
hours at 37 ºC in 5% CO2. Wells were then washed with PBS and cells lyzed as described 
below. 
 
RT-qPCR 
RNA was isolated from whole mouse liver, primary hepatocytes, or liver sinusoidal 
endothelial cells using an RNeasy Mini Kit (whole liver, hepatocytes) or RNeasy Plus Micro 
Kit (liver sinusoidal endothelial cells) (Qiagen, Manchester, UK). cDNA transcription and 
qPCR were performed using a SYBR-GreenER Two-Step qRT-PCR kit (Invitrogen, Thermo 
Fisher Scientific) or QuantiTect Reverse Transcription and SYBR Green PCR Kits (Qiagen). 
Samples were amplified on an ABI 7900HT thermocycler (Applied Biosystems, Thermo Fisher 
Scientific) and normalized to Actb and/or Gapdh expression. Primers used were as follows: 
Actb forward: 5’-TGTTACCAACTGGGACGACA-3’, reverse: 5’-GGGGTGTTGAAGGTCTCAAA-3’; 
Itgb8 forward: 5’-CTGAAGAAATACCCCGTGGA-3’, reverse: 5’-ATGGGGAGGCATACAGTCT-3’. 
Quantitect Primer Assays (Qiagen, 249990) were used for the following genes:  Ccna2 
(QT00102151); Ccnb1 (QT00152040); Ccnd1 (QT00154595); Ccne1 (QT00103495); Cdkn1a 
(QT00137053); Cdkn1b (QT01058708); Gapdh (QT01658692); and Plat (QT00133630). 
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To assess TGFβ signaling, a custom RT2 Profiler PCR array (Qiagen, 330171) was designed 
containing primer sequences for the genes shown in Supplementary Table S1. RNA was 
isolated following primary hepatocyte culture as described above and reversed transcribed 
using the RT2 First Strand Kit (Qiagen, 330401). qPCR was performed using RT2 SYBR Green 
ROX qPCR Mastermix (Qiagen, 330522) on an ABI 7900HT thermocycler (Applied 
Biosystems), normalized to Actb and Gapdh expression. 
 
Hepatocyte adhesion assay 
Adhesion was assessed using a colorimetric ECM Cell Adhesion Array Kit (Millipore, 
ECM540) according to the manufacturer’s instructions. Primary mouse hepatocytes were 
isolated as described above, plated in triplicate at 50,000 cells per well, and incubated for 
two hours at 37 °C in 5% CO2. Absorbance was measured at 570nm using a Synergy HT 
microplate reader (BioTek, Swindon, UK). Relative absorbance was calculated by 
standardizing to absorbance in the Collagen I well, prior to calculation of mean relative 
absorbance for each extracellular matrix protein for each sample. 
 
Hepatocyte proliferation assay 
Primary mouse hepatocytes were isolated as above and plated at 10,000 cells per well in 24-
well plates (Primaria, Corning, St David’s Park, UK, 353847) in DMEM/F-12 supplemented 
with 15mM HEPES (Sigma-Aldrich, H3375), 10% Fetal Bovine Serum, 1% Insulin-Transferrin-
Selenium (Thermo Fisher Scientific, 41400-045), and 1% Penicillin Streptomycin. Cells were 
allowed to adhere for four hours before washing with PBS. Cells were then cultured for 48 
hours in a low-serum version of the plating medium, containing only 0.5% Fetal Bovine 
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Serum. The β8 integrin subunit blocking antibody or non-binding control antibody were 
added at 20µg/mL. Growth factors (Thermo Fisher Scientific, hepatocyte growth factor 
(HGF), PHG0254, epidermal growth factor (EGF), PMG8044) were added at 40ng/mL. 
Culture medium, antibodies, and growth factors were refreshed at 24 hours, at which time 
10µM EdU (5-ethynyl-2'-deoxyuridine, Thermo Fisher Scientific, C10640) was added. After 
the 48-hour culture period, cells were washed with PBS-BSA (PBS supplemented with 1% 
Bovine Serum Albumin (Sigma-Aldrich, A8806)) and then fixed using 4% paraformaldehyde 
in PBS for 15 minutes at room temperature. 
 
Proliferating hepatocytes were detected using the Click-iT Plus EdU Alexa Fluor 647 Imaging 
Kit (Thermo Fisher Scientific, C10640). Briefly, fixed cells were washed with PBS-BSA and 
incubated in 0.5% Triton X-100 (Sigma-Aldrich, T8787) in PBS for 20 minutes at room 
temperature. Following washing, the Click-iT Plus reaction cocktail was added and cells 
incubated for 30 minutes at room temperature and protected from light. The cells were 
washed again and then incubated in 5µg/mL Hoechst 33342 for 30 minutes at room 
temperature and protected from light. Finally, cells were washed with PBS and imaged. 
Imaging was performed using an LSM780 confocal microscope system (Carl Zeiss Ltd, 
Cambridge, UK). Tiled images were acquired, with three non-overlapping areas of 18µm2 
imaged per well. Imaris (version 8.4.1, Bitplane AG, Zurich, Switzerland) was used to identify 
the total (Hoechst-positive) nuclei number and the number of EdU-positive nuclei, and the 
percentage of proliferating nuclei was calculated. 
 
Whole liver microarray 
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Sample preparation, labeling, and array hybridizations were performed using the Agilent GE 
4x44 Mouse microarray platform (Agilent Technologies (Palo Alto, CA); 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL7202; last accessed 13th 
September 2018). Total RNA quality was assessed using a Pico Chip on an Agilent 2100 
Bioanalyzer, and RNA was amplified and labeled with Cy3-CTP using the Agilent low RNA 
input fluorescent linear amplification kits, following the manufacturer’s protocol. Labeled 
cRNA was assessed using the Nanodrop ND-100 (Nanodrop Technologies, Inc., Wilmington 
DE), and equal amounts of Cy3-labeled target were hybridized to Agilent whole mouse 
genome 4x44K Ink-jet arrays (Agilent Technologies, G4122F). Hybridizations were 
performed for 14 hours, according to the manufacturer’s protocol. Arrays were scanned 
using the Agilent microarray scanner and raw signal intensities were extracted with Agilent 
Feature Extraction v10.5 software. Raw data are accessible at the Gene Expression Omnibus 
repository (http://www.ncbi.nlm.nih.gov/geo; accession no. GSE111591; last accessed 13th 
September, 2018). 
 
Human liver tissue 
De-identified sections of uninjured and fibrotic human liver tissue were provided by the 
Lothian NRS Bioresource with approval from Tissue Governance. Samples of 
acetaminophen-injured human liver tissue were obtained as part of the Pathophysiology of 
Acute Liver Injury study. This study was approved by the Scotland A Research Ethics 
Committee and NHS Lothian Research and Development. 
 
Statistics 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 14
The statistical significance of differences between groups was calculated with a 2-tailed 
Student’s t test or Mann Whitney test as appropriate. Differences with a P-value of less than 
0.05 were considered statistically significant. PCR data obtained for individual genes were 
log-transformed prior to analysis and a Bonferroni correction was applied to account for 
multiple testing. PCR array data were standardized as previously reported,37 to identify 
genes in test samples with a 95% confidence interval for standardized relative fold change 
that did not overlap 1 (the value assigned to the fold change for the same gene in control 
samples). 
 
For microarray analysis, differential gene expression was examined with the R package 
limma (version 3.32.7).38 Quality control was performed by identifying outliers in the log2 
intensity between arrays and comparison of multidimensional scaling of distances between 
microarray expression profiles. Background correction was conducted according to the 
normexp method and the data were normalized using the quantile normalization 
method.39,40 A two-way ANOVA linear model was fitted to the comparison to estimate the 
mean M values and calculate moderated t-statistic, B statistic, false discovery rate, and P-
value for each gene for the comparison of interest. Adjusted P-values were produced by the 
method proposed by Holm.41 Gene Ontology (GO) analysis was performed with the R 
package topGO (version 2.28.0),42 and the elim algorithm, combined with the Fisher exact 
test, was used to calculate the enrichment scores for each of the GO terms. 
 
RESULTS 
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Depletion of hepatocyte integrin αvβ8 leads to increased hepatocyte proliferation and 
accelerated liver regeneration 
To deplete integrin αvβ8 in hepatocytes, Itgb8flox/flox;Alb-Cre mice were generated.32,33 
Primary hepatocytes were isolated from Itgb8flox/flox;Alb-Cre mice and Cre-negative 
littermate controls. Quantitative PCR for Itgb8 confirmed expression in control hepatocytes 
and successful depletion in hepatocytes isolated from Itgb8flox/flox;Alb-Cre mice (Fig 1A). 
Assessment of hepatocyte proliferation following two-thirds partial hepatectomy showed 
significantly increased proliferation in Itgb8flox/flox;Alb-Cre mice at 36, 48, and 72 hours 
following liver injury compared to controls (Fig 1B,C). This increased hepatocyte 
proliferation was not followed by an increase in hepatocyte apoptosis at day five post 
partial hepatectomy, when liver regeneration was nearing completion in the Itgb8flox/flox;Alb-
Cre mouse (Supplemental Fig S1). Interestingly, the proportion of hepatocyte mitoses 
(identified morphologically) was decreased in Itgb8flox/flox;Alb-Cre mice at 72 hours following 
liver injury compared to controls (Fig 1D). However, liver-to-body weight ratio was 
significantly increased in Itgb8flox/flox;Alb-Cre mice at 72 and 96 hours after partial 
hepatectomy, demonstrating that the increase in hepatocyte proliferation in Itgb8flox/flox;Alb-
Cre mice detected by BrdU immunohistochemistry resulted in accelerated restoration of 
liver mass compared to control (Fig 1E). 
 
Depletion of hepatocyte integrin αvβ8 does not alter baseline hepatocyte proliferation or 
subsequent inflammatory phenotype 
As integrin αvβ8 is able to activate TGFβ, a well-characterized suppressor of epithelial 
proliferation, it was assessed whether genetic depletion of hepatocyte αvβ8 alters baseline 
hepatocyte proliferation or liver-to-body weight ratio. Hepatocyte BrdU incorporation and 
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mitoses, and liver-to-body weight ratio was measured in uninjured Itgb8flox/flox;Alb-Cre mice 
and controls (Fig 1B, D, E), and no difference was found in any of these variables between 
groups. Furthermore, there was no difference in baseline liver biochemistry, hepatic 
morphology, or resident non-parenchymal cell populations (Kupffer cells and HSCs) between 
uninjured Itgb8flox/flox;Alb-Cre mice and controls (Fig 1F-H, Supplemental Fig S2). Following 
partial hepatectomy, there was also no difference in hepatic inflammation (Kupffer cells or 
neutrophils), or HSC immunostaining (Fig 2A-C). This suggests that the increased liver 
regeneration observed following partial hepatectomy in Itgb8flox/flox;Alb-Cre mice was not 
due to differences in degree of initial injury or the subsequent inflammatory response. 
 
Depletion of HSC integrin αvβ8 does not lead to increased hepatocyte proliferation 
Integrin αvβ8 is also expressed on HSCs.21 As HSCs have been shown to play an important 
regulatory role in liver regeneration,43,44 mice in which integrin αvβ8 had been depleted 
from HSCs (Itgb8flox/flox;Pdgfrb-Cre) were used to examine the role of HSC integrin αvβ8 
during liver regeneration. Following two-thirds partial hepatectomy, there was no 
significant difference in hepatocyte proliferation between Itgb8flox/flox;Pdgfrb-Cre mice and 
controls (Fig 2D). Liver sinusoidal endothelial cells have also been shown to play a key role in 
liver regeneration.45-47 However, integrin αvβ8 expression was not observed in liver 
sinusoidal endothelial cells by qPCR. 
 
Assessment of hepatic cell cycle genes following depletion of hepatocyte integrin αvβ8 
and partial hepatectomy 
To examine whether depletion of hepatocyte integrin αvβ8 might have a direct effect on the 
cell cycle, the expression of genes with key roles in cell cycle regulation was measured at 
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multiple time points following partial hepatectomy. Overall, partial hepatectomy resulted in 
expected changes in gene expression in whole liver from both Itgb8flox/flox;Alb-Cre mice and 
controls (Fig 3A, B, Supplemental Fig S3). There was a trend towards increased expression of 
Ccna2 and Ccnb1 in Itgb8flox/flox;Alb-Cre mice compared to controls; however, this did not 
reach statistical significance at any time point (Fig 3A, B). Analysis of other cell cycle–related 
genes (Ccnd1, Ccne1, Cdkn1a, Cdkn1b) showed no difference between Itgb8flox/flox;Alb-Cre 
mice and controls (Supplemental Fig S3). 
 
Depletion of integrin αvβ8 on hepatocytes does not alter adhesion to multiple matrix 
proteins present in normal and regenerating liver 
Integrin αvβ8 binds extracellular matrix ligands such as vitronectin, fibronectin, collagen IV, 
and fibronectin.48,49 To test whether depletion of integrin αvβ8 on hepatocytes alters 
adhesion to cell matrix proteins present in normal and regenerating liver, an in vitro cell 
adhesion assay with multiple different matrix substrates was used. No difference was found 
in adhesion between Itgb8flox/flox;Alb-Cre and control hepatocytes across all seven matrix 
proteins tested (Fig 3C), suggesting that altered hepatocyte adhesion is not responsible for 
the pro-regenerative phenotype observed in Itgb8flox/flox;Alb-Cre mice. 
 
Inhibition of integrin αvβ8 modulates TGFβ-responsive genes in hepatocytes 
Integrin αvβ8 has previously been shown to play a key role in the activation of latent 
TGFβ,25-31 a potent inhibitor of hepatocyte proliferation.5-7 Therefore, we hypothesized that 
depletion of hepatocyte integrin αvβ8 might promote hepatocyte proliferation through 
modulation of TGFβ signaling pathways. The time course of hepatic Itgb8 expression 
following partial hepatectomy supports a role for integrin αvβ8 as a suppressor of 
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hepatocyte proliferation during liver regeneration (Fig 3D). Hepatic Itgb8 expression falls 
markedly in the 24 hours immediately following partial hepatectomy, and this down-
regulation appears to be permissive for hepatocyte proliferation. As the liver approaches 
full restoration of its functional mass at five days post partial hepatectomy, hepatocyte 
Itgb8 expression peaks at 10 times baseline expression, consistent with a role for integrin 
αvβ8 as a brake on hepatocyte proliferation (Fig 3D). 
 
Detecting the modulation of TGFβ activation in the hepatocyte regenerative niche is very 
challenging, as it is not possible to measure the levels of active TGFβ in tissue directly. 
Therefore, an experiment was designed to examine how inhibition of integrin αvβ8 might 
modulate TGFβ-responsive genes in primary mouse hepatocytes (Fig 3E). Firstly, a custom 
qPCR array was designed, containing 87 genes either shown to be responsive to TGFβ 
signaling in hepatocytes50 or comprising components of the TGFβ pathway (Supplemental 
Table S1). Primary murine hepatocytes were isolated from wild-type mice and plated onto 
collagen in the presence of either a β8 integrin subunit blocking antibody or a non-binding 
control antibody.26 After incubation for 24 hours, hepatocytes were lyzed, RNA was 
extracted, and gene expression quantified using the custom qPCR array. Data were then 
standardized as previously described by Willems et al37 Following culture with β8 integrin 
subunit blocking antibody, 20 genes in the qPCR array were found to have a detectable 
change in expression with a 95% confidence interval which did not overlap control values 
(Fig 3F). Of these, 12 genes showed greater than 10% up- or down-regulation when 
compared to controls, with 10 out of 12 responding as predicted. Plat, encoding tissue 
plasminogen activator (tPA), showed the greatest up-regulation. Hepatocyte expression of 
Plat has been shown to decrease in the presence of TGFβ,50 whereas expression increased 
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three-fold in wild-type hepatocytes treated with β8 integrin subunit blocking antibody. 
Increased expression of Plat was not observed when hepatocytes from Itgb8flox/flox;Alb-Cre 
mice were treated with β8 integrin subunit blocking antibody, suggesting the observed 
response is specific to β8 integrin subunit inhibition (Supplemental Fig S4). Conversely, 
hepatocyte expression of the TGFβ-responsive gene Hmox1 (heme oxygenase 1) was down-
regulated in the presence of β8 integrin subunit blocking antibody. These data demonstrate 
that inhibition of integrin αvβ8 modulates TGFβ-responsive genes in hepatocytes, 
suggesting a possible mechanism through which integrin αvβ8 depletion promotes 
hepatocyte proliferation. 
 
Inhibition of hepatocyte integrin αvβ8 does not alter the proliferative response to 
mitogenic growth factors 
Hepatocyte growth factor (HGF) and epidermal growth factor (EGF) are key drivers of liver 
regeneration.8 To investigate whether integrin αvβ8 might have a role in regulating the 
hepatocyte response to these direct mitogens, the effect of β8 integrin subunit inhibition 
during in vitro proliferation of primary hepatocytes in response to EGF and HGF was 
examined. A robust increase in hepatocyte proliferation was achieved with addition of 
either, or both, EGF and HGF, compared to standard culture medium (Fig 3G). However, 
inhibition of integrin αvβ8 had no effect on the degree of in vitro hepatocyte proliferation. 
This suggests that the accelerated liver regeneration observed following hepatocyte integrin 
αvβ8 depletion does not occur via modulation of HGF or EGF downstream signaling 
pathways. 
 
Microarray analysis of whole liver from control and Itgb8
flox/flox
;Alb-Cre mice 
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To explore further the potential mechanisms by which inhibition of integrin αvβ8 increases 
hepatocyte proliferation and accelerates liver regeneration, global gene expression changes 
were examined by microarray analysis of whole liver. Samples were obtained from control 
and Itgb8flox/flox;Alb-Cre mice prior to, and at 24 hours post, partial hepatectomy. From 
26,136 transcripts, 1,080 showed statistically significant differential expression following 
partial hepatectomy. Three-hundred and thirty of these occurred only in the Itgb8flox/flox;Alb-
Cre mouse (Fig 4A). Gene ontology (GO) analysis was performed on the differentially 
expressed genes. The dominant GO terms enriched in genes up-regulated exclusively in 
Itgb8
flox/flox
;Alb-Cre mice following partial hepatectomy are shown in Figure 4B. The majority 
of these terms relate to cytoskeletal organization and cellular adhesion. Similarly, the 
dominant GO terms enriched in genes down-regulated exclusively in Itgb8flox/flox;Alb-Cre 
mice following partial hepatectomy are shown in Figure 4C. These terms were relatively 
non-specific, relating to a range of intracellular metabolic processes. 
 
Given the increased hepatocyte proliferation observed following partial hepatectomy in 
Itgb8
flox/flox
;Alb-Cre mice, changes in expression of genes known to regulate the cell cycle 
were specifically studied. However, when comparing post partial hepatectomy samples 
from Itgb8flox/flox;Alb-Cre mice and controls, no significant difference in the expression of cell 
cycle genes was detected by microarray. This mirrors the findings of both our examination 
of cell cycle gene expression in whole liver pre and post partial hepatectomy (Fig 3A, B and 
Supplemental Fig S3) and the qPCR array in cultured hepatocytes treated with β8 integrin 
subunit blocking antibody, in which no consistent changes in gene expression were noted in 
the 10 cell-cycle and proliferation genes included in the array (Supplemental Table S1). 
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Depletion of hepatocyte integrin αvβ8 does not increase tumor formation in a mouse 
model of HCC 
 In addition to promoting hepatocyte proliferation, disruption of TGFβ signaling can 
accelerate the development of HCC in mice following DEN administration.12 As depletion of 
integrin αvβ8 on hepatocytes increased hepatocyte proliferation and accelerated liver 
regeneration following injury, and blockade of hepatocyte integrin αvβ8 in vitro modulated 
TGFβ-responsive genes, the possibility that this pro-proliferative phenotype might increase 
the risk of HCC development was also assessed. Itgb8flox/flox;Alb-Cre and control mice were 
injected with DEN at 12 to 14 days of age to induce HCC (Fig 5A). Following sacrifice at forty 
weeks, the number and size of tumors in each liver was quantified (Fig 5B). There was no 
difference in either tumor number or median tumor size between Itgb8flox/flox;Alb-Cre and 
control mice (Fig 5C, D). This demonstrates that depletion of hepatocyte integrin αvβ8 does 
not predispose to increased tumor formation in this mouse model of HCC. 
 
Human hepatocytes express integrin αvβ8 and represent a viable therapeutic target to 
promote liver regeneration in patients with liver disease 
To assess the potential utility of integrin αvβ8 as a therapeutic target to promote 
hepatocyte proliferation and liver regeneration in patients with liver disease, the expression 
of integrin αvβ8 was assessed in samples of human liver. Uninjured liver tissue and tissue 
obtained from patients with acute liver failure secondary to acetaminophen overdose or 
from patients with cirrhosis was stained for the β8 integrin subunit. Widespread expression 
in hepatocytes was detected in all samples, demonstrating that integrin αvβ8 is a viable 
potential therapeutic target in patients with a broad range of liver diseases (Fig 5E). 
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DISCUSSION 
 
We show that depletion of hepatocyte integrin αvβ8 leads to increased hepatocyte 
proliferation and accelerated liver regeneration following partial hepatectomy in mice. The 
time course of hepatic Itgb8 expression following partial hepatectomy, namely a rapid 
down-regulation followed by rebound up-regulation as the liver returns to its normal size, is 
consistent with a role for integrin αvβ8 as a brake on hepatocyte proliferation. This anti-
proliferative role for integrin αvβ8 appears to be mediated via TGFβ, rather than altered 
hepatocyte adhesion, since blocking integrin αvβ8 on hepatocytes alters TGFβ-responsive 
gene expression. Importantly, the augmentation in hepatocyte proliferation in 
Itgb8
flox/flox
;Alb-Cre mice was not accompanied by increased susceptibility to hepatocellular 
tumor formation. Finally, human hepatocytes also express integrin αvβ8 in both acute and 
chronic liver disease, and therefore integrin αvβ8 represents a viable therapeutic target to 
promote liver regeneration in patients with a broad range of liver diseases. 
 
Integrin αvβ8 has previously been shown to have a key regulatory role in the activation of 
latent TGFβ.25-31 The inhibitory effect of active TGFβ on hepatocyte proliferation is well-
established, including evidence demonstrating tonic inhibition of hepatocyte proliferation in 
the uninjured liver.5-7 The rapid down-regulation of hepatic Itgb8 expression observed 
following partial hepatectomy is in line with the hypothesis that a reduction in integrin 
αvβ8–mediated activation of TGFβ is permissive for a pro-regenerative environment in the 
liver. Demonstrating subtle changes in activation status of TGFβ within the hepatic 
regenerative niche is very challenging, given the magnitude and localized nature of these 
changes, and also the small amount of remnant tissue present following two-thirds partial 
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hepatectomy. However, inhibition of hepatocyte integrin αvβ8 in vitro, using a β8 integrin 
subunit blocking antibody, resulted in changes in expression of multiple TGFβ-responsive 
genes such as Plat and Hmox1. Tissue plasminogen activator, encoded by Plat, can activate 
HGF51 and has been shown to play a role in liver lobule reorganization following acute 
injury.52 Knockout of tPA in mice worsens injury following bile duct ligation, but this 
phenotype is reversed by administration of HGF.53 These data suggest that the regulatory 
role of integrin αvβ8 during hepatocyte proliferation is, at least in part, mediated via TGFβ 
signaling, and that integrin αvβ8 depletion or inhibition may drive hepatocyte proliferation 
through tPA-mediated activation of HGF. Inhibition of hepatocyte integrin αvβ8 did not alter 
the proliferative response to stimulation with EGF and HGF in vitro, suggesting that the 
accelerated liver regeneration observed following hepatocyte integrin αvβ8 depletion does 
not occur via modulation of HGF or EGF downstream signaling pathways. 
 
Detectable changes in the expression of genes regulating the cell cycle were identified 
following partial hepatectomy, similar to those previously reported,54 but did not differ 
between Itgb8flox/flox;Alb-Cre mice and controls. Inhibiting integrin αvβ8 in vitro also had no 
effect on expression of cell cycle genes, as measured by qPCR gene array. This would 
suggest that depletion of integrin αvβ8 on hepatocytes does not appear to change the 
kinetics of cell cycle regulation in the individual cell. Instead, depletion of hepatocyte 
integrin αvβ8 may promote liver regeneration by permitting a greater number of 
hepatocytes to escape the anti-proliferative effects of active TGFβ. The observation of a 
reduction in the proportion of hepatic mitoses in Itgb8flox/flox;Alb-Cre mice compared to 
controls at 72 hours post partial hepatectomy is difficult to reconcile with the increase in 
BrdU incorporation and the accelerated restoration of total liver mass. Although no change 
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was detected in cell cycle kinetics, if the overall time in M phase were reduced in 
hepatocytes of Itgb8flox/flox;Alb-Cre mice, this could decrease the proportion of mitotic 
hepatocytes at any single point in time. Previous work has demonstrated a strong effect of 
circadian rhythm on hepatocyte entry into M phase following partial hepatectomy in mice, 
an effect not seen when assessing BrdU incorporation.55 However, in this study, partial 
hepatectomy was always performed in the morning and experimental order randomized, so 
this should not account for differences between Itgb8flox/flox;Alb-Cre mice and controls. 
 
To screen for additional pathways that might be regulated by integrin αvβ8, gene expression 
was assessed using microarray in whole liver samples from Itgb8flox/flox;Alb-Cre mice and 
controls, comparing gene expression in uninjured liver and 24 hours post partial 
hepatectomy. Despite observing a large number of changes in gene expression (330) 
following partial hepatectomy that were restricted to Itgb8flox/flox;Alb-Cre mice, there were 
again no differences in expression of genes regulating the cell cycle or proliferation, when 
compared to control mice. The failure to detect changes in expression of genes regulating 
the cell cycle may also reflect limitations in sensitivity, particularly of the microarray 
technique, when applied to whole liver lysates from Itgb8flox/flox;Alb-Cre mice and controls. 
Even following partial hepatectomy, only a minority of hepatocytes will be proliferating at 
any one time and the presence of non-parenchymal cell mRNA in the whole liver lysates 
that were analyzed will further reduce the signal-to-noise ratio. 
 
Gene ontology analysis of genes up-regulated only in Itgb8flox/flox;Alb-Cre mice following 
partial hepatectomy returned multiple terms relating to cytoskeletal organization and 
extracellular adhesion. Integrins are well-known for their role in extracellular adhesion and 
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their cytoplasmic domains can bind the cytoskeleton.14 However, it has previously been 
suggested that the cytoplasmic domain of the β8 subunit does not bind the cytoskeleton.48 
Furthermore, no difference was found in the ability of hepatocytes isolated from 
Itgb8
flox/flox
;Alb-Cre mice and controls to adhere to multiple extracellular matrix proteins 
found in both normal and regenerating liver. 
 
Targeting of TGFβ pathways has been a major focus of research across several fields, 
particularly in the context of inflammation, wound healing, and oncogenesis. Unfortunately, 
global inhibition of TGFβ signaling can be associated with serious, undesirable effects, 
including excessive inflammation and development of neoplasia.10-12 This is highly likely to 
be due to the pleiotropic, context-dependent functions of TGFβ. Selective targeting of TGFβ 
activation by inhibition of integrin αvβ8 in the hepatic regenerative niche may potentially 
avoid many of the adverse effects noted with pan-TGFβ blockade, while still promoting the 
desired effects on hepatocyte proliferation and liver regeneration. Importantly, these 
results did not demonstrate an increase in either hepatic inflammation or carcinogenesis in 
mice following depletion of hepatocyte integrin αvβ8. 
 
Human hepatocytes express integrin αvβ8 in uninjured liver, following acute hepatic injury 
secondary to acetaminophen overdose, and also in cirrhosis. Therefore, hepatocyte integrin 
αvβ8 appears to be a viable translational target. There are potentially multiple clinical 
scenarios to which integrin αvβ8 inhibition could be applied. For example, using αvβ8 
inhibition as a pro-regenerative therapy in the setting of acute liver failure may obviate the 
requirement for, or buy more time prior to, liver transplantation. Furthermore, combination 
with anti-fibrotic therapies could permit the restoration of functional, parenchymal liver 
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mass in tandem with a reduction in fibrosis in patients with chronic liver disease. It might 
also allow more patients with primary or metastatic liver cancer to be treated successfully. 
 
In summary, depletion of integrin αvβ8 on murine hepatocytes leads to increased 
hepatocyte proliferation and accelerated liver regeneration. Targeting integrin αvβ8 may 
therefore represent a promising therapeutic strategy to drive liver regeneration in patients 
with a broad range of liver diseases. 
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Figure Legends 
 
Figure 1 Genetic depletion of hepatocyte integrin αvβ8 accelerates liver regeneration. A: 
qPCR of Itgb8 expression in hepatocytes isolated from control and Itgb8flox/flox;Alb-Cre (β8-
AlbCre) mice (n=3). B: Quantitation of BrdU+ hepatocyte nuclei in control and β8-AlbCre 
mice after partial hepatectomy (n=3 to 6). C: Representative images from BrdU 
immunostaining of liver sections from control and β8-AlbCre mice at 0 and 48 hours after 
partial hepatectomy. Quantitation of hepatocyte mitoses (D) and liver-to-body weight ratio 
(E) in control and β8-AlbCre mice after partial hepatectomy (n=3 to 6). F: Serum 
biochemistry (total bilirubin, alanine transaminase (ALT), alkaline phosphatase (ALP), 
albumin) from uninjured control and β8-AlbCre mice (n=6). G and H: Quantification and 
representative images from F4/80 (Kupffer cell, G) and PDGFRβ (HSC, H) immunostaining of 
liver tissue from uninjured control and β8-AlbCre mice (n=6). All data presented as mean; 
error bars – SEM. *P < 0.05, **P < 0.01, ****P < 0.0001. Scale bars 100µm. 
 
Figure 2 Depletion of hepatocyte integrin αvβ8 does not alter inflammatory phenotype 
following partial hepatectomy. A-C: Quantification and representative images from F4/80 
(Kupffer cell, A), GR1 (neutrophil, B), and PDGFRβ (HSC, C) immunostaining of liver tissue 
from control and Itgb8flox/flox;Alb-Cre (β8-AlbCre) mice at 48 hours post partial hepatectomy 
(n=5). D: Quantitation of BrdU+ hepatocyte nuclei and representative images of BrdU 
immunostaining of liver tissue from control and Itgb8flox/flox;Pdgfrb-Cre (β8-PdgfrbCre) mice 
at 48 hours post partial hepatectomy (n=4 and 8). All data presented as mean; error bars – 
SEM. Scale bar 100µm. 
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Figure 3 Investigation of the mechanisms mediating the pro-regenerative effect of 
hepatocyte integrin αvβ8 depletion. A, B: Whole liver expression of cell cycle genes Ccna2 
(A) and Ccnb1 (B) from control and Itgb8flox/flox;Alb-Cre (β8-AlbCre) mice following partial 
hepatectomy (n=4 to 6 per time point). C: Isolated hepatocytes from control and β8-AlbCre 
mice (n=4) were tested in a colorimetric extracellular matrix adhesion assay (BSA, bovine 
serum albumin; Col, collagen). D: Whole liver expression of Itgb8 following partial 
hepatectomy (n=3 to 6 per time point). E: Schematic of experimental design to test the 
effect of a β8 integrin subunit blocking antibody on hepatocyte expression of transforming 
groath factor (TGF)-β–responsive genes. F: Fold regulation of genes from the qPCR array 
with a detectable change in hepatocyte expression following culture with β8 integrin 
subunit blocking antibody (n=3). G: Proliferation of primary hepatocytes cultured for 48 
hours with β8 integrin subunit blocking antibody or control antibody in culture medium 
(Control) and with addition of either epidermal growth factor (EGF), hepatocyte growth 
factor (HGF), or both (n=3). All data presented as mean; error bars – SEM. 
 
Figure 4 Microarray analysis of whole liver (uninjured and 24 hours post partial 
hepatectomy) from control and Itgb8flox/flox;Alb-Cre (β8-AlbCre) mice. A: Summary of the 
number of transcripts with significant changes in expression following partial hepatectomy 
in β8-AlbCre mice and controls (n = 4 per group per time point). B and C: The top 10 GO 
terms enriched in those genes either up-regulated (B) or down-regulated (C) exclusively in 
β8-AlbCre mice following partial hepatectomy. 
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Figure 5 Depletion of hepatocyte integrin αvβ8 does not increase HCC in mice, whereas 
human hepatocytes express integrin αvβ8 in acute and chronic liver disease. A: Schematic of 
mouse model of HCC (i.p., intraperitoneal). B: Representative images of livers from control 
and Itgb8flox/flox;Alb-Cre (β8-AlbCre) mice at harvest. C and D: Quantification of tumor 
number (C) and median tumor size (D) in control and β8-AlbCre mice at 40 weeks 
(horizontal bar indicates mean, n=16 and 14). E: Representative low- and high-power images 
of β8 integrin subunit immunostaining in uninjured human liver tissue (n=5), following 
acetaminophen overdose (n=5), or in cirrhosis (n=6). Scale bars 250µm (upper) and 100µm 
(lower). 
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